Hung H M James, Wang Sue-Jane, O'Neill Robert
Division of Biometrics I, Office of Biostatistics, OTS/CDER, FDA, Silver Spring, MD 20993-0002, USA.
J Biopharm Stat. 2007;17(2):201-13. doi: 10.1080/10543400601177343.
Noninferiority trials without a placebo arm often require an indirect statistical inference for assessing the effect of a test treatment relative to the placebo effect or relative to the effect of the selected active control treatment. The indirect inference involves the direct comparison of the test treatment with the active control from the noninferiority trial and the assessment, via some type of meta-analyses, of the effect of the active control relative to a placebo from historical studies. The traditional within-noninferiority-trial Type I error rate cannot ascertain the statistical risks associated with the indirect inference, though this error rate is of the primary consideration under the frequentist statistical framework. Another kind of Type I error rate, known as across-trial Type I error rate, needs to be considered in order that the statistical risks associated with the indirect inference can be controlled at a small level. Consideration of the two kinds of Type I error rates is also important for defining a noninferiority margin. For the indirect statistical inference, the practical utility of any method that controls only the across-trial Type I error rate at a fixed small level is limited.
没有安慰剂组的非劣效性试验通常需要进行间接统计推断,以评估试验治疗相对于安慰剂效应或相对于所选活性对照治疗效应的效果。间接推断包括在非劣效性试验中将试验治疗与活性对照进行直接比较,以及通过某种类型的荟萃分析评估活性对照相对于历史研究中安慰剂的效果。传统的非劣效性试验内I型错误率无法确定与间接推断相关的统计风险,尽管在频率主义统计框架下,该错误率是首要考虑因素。为了将与间接推断相关的统计风险控制在较小水平,需要考虑另一种I型错误率,即跨试验I型错误率。考虑这两种I型错误率对于定义非劣效性界值也很重要。对于间接统计推断,任何仅将跨试验I型错误率控制在固定小水平的方法的实际效用都是有限的。